Publisher
Springer Nature Switzerland
Reference12 articles.
1. Elliott, P., et al.: 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur. Heart J. 35(39), 2733–2779 (2014). https://doi.org/10.1093/eurheartj/ehu284
2. Nishimura, R.A., Ommen, S.R., Tajik, A.J.: Hypertrophic cardiomyopathy, a patient perspective. Circulation 108(19), 133-e135 (2003). https://doi.org/10.1161/01.CIR.0000097621.97566.96
3. SILICOFCM H2020 project: In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy. 777204, 2018–2022 (2022). www.silicofcm.eu
4. Filipovic, N., et al.: In silico clinical trials for cardiovascular disease. J. Visual. Exp. 183 (2022). https://doi.org/10.3791/63573
5. Filipovic, N., et al.: SILICOFCM platform, multiscale modeling of left ventricle from echocardiographic images and drug influence for cardiomyopathy disease. Comput. Methods Programs Biomed. 227, 107194 (2022). https://doi.org/10.1016/j.cmpb.2022.107194